Audiologists in Saint Joseph, MI Accepting Medicare

6 Audiologists found. Showing 1 - 6

Dr. Terry L Mcilvaine, AU.D. Audiologist Medicare: Medicare Enrolled Practice Location: 511 Renaissance Dr, Suite 100, Saint Joseph, MI 49085 Phone: 269-982-3444    Fax: 269-982-3445

Grady Hilge, AU.D. Audiologist Medicare: Not Enrolled in Medicare Practice Location: 511 Renaissance Dr Ste 100, Saint Joseph, MI 49085 Phone: 269-982-3444

Professional Hearing Services, Ltd Audiologist Medicare: Medicare Enrolled Practice Location: 511 Renaissance Dr, Ste 100, Saint Joseph, MI 49085 Phone: 269-982-3444    Fax: 269-982-3445

Ms. Cathleen A Burns, MA, CCC-A Audiologist Medicare: Accepting Medicare Assignments Practice Location: 2680 S Cleveland Ave, Saint Joseph, MI 49085 Phone: 269-982-3368

Mrs. Gyl A. Kasewurm, AUD, FAAA Audiologist Medicare: Accepting Medicare Assignments Practice Location: 511 Renaissance Dr, Ste 100, Saint Joseph, MI 49085 Phone: 269-982-3444    Fax: 269-982-3445

Hannah Barclay Reeg, AU.D. Audiologist Medicare: Not Enrolled in Medicare Practice Location: 511 Renaissance Dr Ste 100, Saint Joseph, MI 49085 Phone: 269-982-3444

News Archive

HHS' new rules on electronic payments could benefit doctors, hospitals

NPR reports on how efforts to set uniform standards for electronic claims for health care services could pay off.

Cedars-Sinai researchers move closer to developing biological pacemaker with new $3 million NIH grant

With a new $3 million grant from the National Institutes of Health, Cedars-Sinai Heart Institute investigators are moving closer to their goal of developing a biological pacemaker that can treat patients afflicted with slow heartbeats.

Micromet to initiate MEDI-565 Phase 1 trial in patients with advanced gastrointestinal cancer

Micromet, Inc. today announced that its licensee for MT111, MedImmune, plans to initiate a Phase 1 trial in patients with advanced gastrointestinal cancers based on an investigational new drug (IND) application recently accepted by the U.S. Food and Drug Administration (FDA).

First trial to investigate new drug combination for NSCLC

Cancer Research UK's Drug Development Office has opened the first trial of a new drug combination in patients with advanced solid tumours and in a subset of patients who have non-small cell lung cancer. This trial will combine two compounds that aim to starve the tumours while simultaneously blocking cancer cell growth.

Read more Medical News

› Verified 8 days ago